EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025

Camille N Kotton iD, Martina Sester iD, Julian Torre-Cisneros iD, International CMV Symposium Faculty

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70223 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Camille N Kotton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Bost…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Organ Transplantation. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotest AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2025 International CMV Symposium convened in Königstein, Germany, bringing together transplant clinicians and researchers to address cytomegalovirus management following the publication of three major guidelines in 2025. The Transplantation Society, European Conference on Infections in Leukaemia, and American Society for Transplantation and Cellular Therapy each released updated recommendations reflecting significant advances, including letermovir prophylaxis for hematopoietic stem cell and high‐risk renal transplantation, maribavir for resistant or refractory disease, and cell‐mediated immunity testing to guide personalized prevention strategies. This review synthesizes symposium discussions, emphasizing translation of evidence‐based recommendations into clinical practice across diverse healthcare settings. Key topics included risk‐stratified prevention approaches balancing efficacy with practical implementation, precision medicine through immune biomarkers, adoptive cellular therapies advancing from experimental to clinical platforms, and vaccine development showing renewed promise after decades of setbacks. Symposium faculty highlighted persistent challenges despite recent progress, such as late‐onset disease after extended prophylaxis, economic barriers limiting access to novel therapies and diagnostics, resistance patterns evolving with increasing antiviral use, and infrastructure requirements for preemptive strategies that may be prohibitive in many settings. Case presentations illustrated real‐world practical challenges to effective guideline implementation. The integration of solid organ and hematopoietic stem cell transplant expertise enabled cross‐disciplinary learning while respecting population‐specific differences. As the transplant community advances toward defeating the “troll of transplantation,” continued therapeutic innovation must be coupled with implementation science, economic analyses, and global cooperation to ensure all transplant recipients benefit from these advances. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsOrgan TransplantationHumansCytomegalovirusHematopoietic Stem Cell TransplantationPractice Guidelines as TopicAcetatesQuinazolinesDichlororibofuranosylbenzimidazoleBenzamidesKidney Transplantation

Stichwörter der Autor:innen

CMV immunoglobulincell‐mediated immunitycytomegalovirusguidelineshematopoietic stem cell transplantationsolid organ transplantationvaccines

Substanzen

Antiviral AgentsletermovirmaribavirAcetatesQuinazolinesDichlororibofuranosylbenzimidazoleBenzamides

Autor:innen und Institutionen

  • Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Transplant and Infection Immunology, Saarland University, Campus Homburg, Homburg, Germany.
  • Center for Gender-specific Biology and Medicine (CGBM), Saarland University, Homburg, Germany.
  • Service of Infectious Diseases, Reina Sofia University Hospital, Maimónides Institute for Biomedical Research of Córdoba (IMIBIC), University of Córdoba (UCO), Córdoba, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

ORCID-Profile: Camille N Kotton, Martina Sester, Julian Torre-Cisneros

Förderung

  • Biotest AG

Zitieren

APA

Kotton, C. N., Sester, M., Torre-Cisneros, J., & International CMV Symposium Faculty (2026). The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025. Transplant Infectious Disease. https://doi.org/10.1111/tid.70223

Vancouver

Kotton CN, Sester M, Torre-Cisneros J, International CMV Symposium Faculty. The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025. Transplant Infectious Disease. 2026. doi:10.1111/tid.70223

BibTeX
@article{Kotton2026,
  author = {Kotton, Camille N and Sester, Martina and Torre-Cisneros, Julian and International CMV Symposium Faculty, International CMV Symposium Faculty},
  title = {The Troll Is Weakened but Not yet Defeated: An Update on Cytomegalovirus Management in Transplantation From the International CMV Symposium 2025},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70223}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche